⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29257444 | 1.00 | — | — | |
| SCHEMBL7153761 | 1.00 | — | — | |
| SCHEMBL489381 | 1.00 | — | — | |
| SCHEMBL27832365 | 0.83 | — | — | |
| SCHEMBL29367973 | 0.80 | — | — | |
| SCHEMBL1782900 | 0.78 | — | — | |
| SCHEMBL14151245 | 0.76 | — | — | |
| SCHEMBL29519762 | 0.76 | — | — | |
| SCHEMBL7095495 | 0.76 | — | — | |
| SCHEMBL1784351 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N V (BE) | 2026-05-21 | — | — | US | disclosed |
| US-20250361477-A1 | PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL | INBIOSE NV (BE) | 2025-11-27 | — | — | US | disclosed |
| US-20250188503-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2025-06-12 | — | — | US | disclosed |
| US-20250188504-A1 | PRODUCTION OF A MIXTURE OF MAMMALIAN MILK OLIGOSACCHARIDES BY A CELL | INBIOSE N.V. (BE) | 2025-06-12 | — | — | US | disclosed |
| US-20250043253-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2025-02-06 | — | — | US | disclosed |
| US-20240368651-A1 | CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| US-20240327888-A1 | LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES | INBIOSE N.V. (BE) | 2024-10-03 | — | — | US | disclosed |
| US-20240294958-A1 | EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS | INBIOSE NV (BE) | 2024-09-05 | — | — | US | disclosed |
| US-20240294959-A1 | CELLULAR PRODUCTION OF BIOPRODUCTS | INBIOSE N.V. (BE) | 2024-09-05 | — | — | US | disclosed |
| US-12077788-B2 | Production of a mixture of neutral non-fucosylated oligosaccharides by a cell | INBIOSE N.V. (BE) | 2024-09-03 | — | — | US | disclosed |
| CN-105163785-A | Methods for treating respiratory diseases and formulations therefor | CEMPRA PHARMACEUTICALS INC | 2015-12-16 | — | — | CN | disclosed |
| CN-104661650-A | Pharmaceutical composition comprising rebamipide | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| CN-103142520-B | Kelimycin tablet and preparation method thereof | Shenyang tonglian group co ltd | 2015-04-01 | — | — | CN | disclosed |
| CN-104105489-A | Application of nematode micromolecules | CALIFORNIA INSTTITUTE OF TECHNOLOGY | 2014-10-15 | — | — | CN | disclosed |
| CN-103142520-A | Kelimycin tablet and preparation method thereof | Shenyang tonglian group co ltd | 2013-06-12 | — | — | CN | disclosed |
| CN-102006890-A | Targeting lipids | ALNYLAM PHARMACEUTICALS INC | 2011-04-06 | — | — | CN | disclosed |
| CN-1756554-A | Novel chemical entities and methods for their use in the treatment of metabolic disorders | ACCERA INC (US) | 2006-04-05 | — | — | CN | disclosed |
| CN-1237976-C | Bite spiramycin and its use in anti inflammatory disease | TONGLIAN GROUP CO LTD SHENYANG (CN) | 2006-01-25 | — | — | CN | disclosed |
| CN-1554355-A | Bite spiramycin and its use in anti inflammatory disease | 沈阳同联集团有限公司 | 2004-12-15 | — | — | CN | disclosed |
| CN-1237911-A | Optical diagnostic agents for diagnosis of neurodenerative diseases by means of near infra-red radiation (NIR-Radiation) | DIAGNOSTIKFORSCHUNG INST (DE) | 1999-12-08 | — | — | CN | disclosed |